Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Thomas

Showing results (121-130 of 217) with videos related to

Pageof 22
Sort By:
British Journal of Haematology|August 23, 2023
Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literatureJun Yen Ng, Linda Warwick, Paul Craft, et al.
Plos One|July 30, 2013
High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohortGillian Mitchell, Mandy L Ballinger, Stephen Wong, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 1, 2017
Estimating <i>TP53</i> Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPROGang Peng, Jasmina Bojadzieva, Mandy L Ballinger, et al.
Therapeutic Advances in Medical Oncology|September 4, 2024
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation frameworkDoah Cho, Sarah J Lord, Robyn Ward, et al.
Cancer|February 3, 2011
RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic modelJonathan C M Clark, Toru Akiyama, David M Thomas, et al.
Future Oncology (London, England)|June 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST programDerrick H W Siu, Frank P Y Lin, David M Thomas, et al.
Journal of Neurochemistry|March 27, 2012
Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivityMariana Angoa-Pérez, Michael J Kane, Denise I Briggs, et al.
International Journal of Cancer|April 25, 2009
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthoodKenneth K Khamly, Vicky J Thursfield, Michael Fay, et al.
The Oncologist|May 7, 2024
From ownership to custodianship of tumor biopsy tissue in genomic testing: a mixed methods study of patient viewsMegan C Best, Phyllis Butow, Jacqueline Savard, et al.
The Journal of Molecular Diagnostics : JMD|April 5, 2011
Cyclin E1 is amplified and overexpressed in osteosarcomaWilliam W Lockwood, Deirdre Stack, Thomas Morris, et al.
Pageof 22

Showing results (121-130 of 217) with videos related to

Sort By:
Pageof 22
British Journal of Haematology|August 23, 2023
Myelodysplastic syndrome and multiple solid tumours in an individual with compound heterozygous deleterious FANCM variants: A case report and review of the literatureJun Yen Ng, Linda Warwick, Paul Craft, et al.
Plos One|July 30, 2013
High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohortGillian Mitchell, Mandy L Ballinger, Stephen Wong, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 1, 2017
Estimating <i>TP53</i> Mutation Carrier Probability in Families with Li-Fraumeni Syndrome Using LFSPROGang Peng, Jasmina Bojadzieva, Mandy L Ballinger, et al.
Therapeutic Advances in Medical Oncology|September 4, 2024
Criteria for assessing evidence for biomarker-targeted therapies in rare cancers-an extrapolation frameworkDoah Cho, Sarah J Lord, Robyn Ward, et al.
Cancer|February 3, 2011
RECK in osteosarcoma: a novel role in tumour vasculature and inhibition of tumorigenesis in an orthotopic modelJonathan C M Clark, Toru Akiyama, David M Thomas, et al.
Future Oncology (London, England)|June 16, 2026
Time-to-progression ratio as a potential study endpoint in early-phase oncology trials: pooled analysis of phase II trials from the Australian MoST programDerrick H W Siu, Frank P Y Lin, David M Thomas, et al.
Journal of Neurochemistry|March 27, 2012
Genetic depletion of brain 5HT reveals a common molecular pathway mediating compulsivity and impulsivityMariana Angoa-Pérez, Michael J Kane, Denise I Briggs, et al.
International Journal of Cancer|April 25, 2009
Gender-specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthoodKenneth K Khamly, Vicky J Thursfield, Michael Fay, et al.
The Oncologist|May 7, 2024
From ownership to custodianship of tumor biopsy tissue in genomic testing: a mixed methods study of patient viewsMegan C Best, Phyllis Butow, Jacqueline Savard, et al.
The Journal of Molecular Diagnostics : JMD|April 5, 2011
Cyclin E1 is amplified and overexpressed in osteosarcomaWilliam W Lockwood, Deirdre Stack, Thomas Morris, et al.
Pageof 22